Longevity
Investors
Conference

September 28-30, 2022

In-person conference

 

Gstaad, Switzerland

Calender.png
asd.png
Untitled-3.png
  • LinkedIn
  • Twitter
  • Instagram

About the conference 

The Longevity Investors Conference is the world’s leading and most private longevity-focus investors only conference.

LIC provides relevant insights into the longevity subject, expert education, investment opportunities, excellent networking opportunities and a great setting in an exclusive location.

The two full days conference is bringing together the world’s top longevity KOLs, institutional and private investors, wealthy private investors, family offices and funds.

What is Longevity?

Longevity is the science of anti-aging research and rejuvenation.

 

It has experienced an unprecedented advance over recent years, particularly with the discovery that the rate of aging is controlled, at least to some extent, by genetic pathways and biochemical processes.

Longevity identifies both lifestyle and pharmaceutical targets to improve the human health-span (i.e.the time we can live without any negative impact from aging.)

Longevity will be one of the largest, if not the largest, investment opportunity in the decades to come.

 

Why join the LIC?

  • High Quality Networking: The LIC is not a mass event.The number of participants is limited to 150, which ensures a private atmosphere in a beautiful setting. Investors can meet other investors as well as leading longevity experts and KOLs.

  • Personal knowledge transfer from best-in-field industry and academic speakers

  • Learn first-hand about attractive investment and business opportunities in the longevity space.

  • Establish strategic partnerships with other business leaders in one of a kind setting in 5*hotel in Gstaad, one of the most exclusive Swiss mountain resorts.

  • Get acquainted and experience with the latest trends related to personal longevity (supplements, therapies, and many more).

Screenshot 2022-02-17 at 17.59.25.png

Investors

Screenshot 2022-02-17 at 17.59.34.png

C-level Executives

Screenshot 2022-02-17 at 17.59.41.png

Academia

Screenshot 2022-02-17 at 17.58.35.png

30+

Outstanding Speakers

Screenshot 2022-02-17 at 17.58.42.png

100-150

Hand-picked delegates

Screenshot 2022-02-17 at 17.59.02.png

2 full-days

Conference

Tickets

CHIC ROOM

CHIC ROOM

Package with accommodation

Regular Price:         3900 CHF

Early bird:               3300 CHF

Includes:

  • 2-nights stay in a Chic room at Le Grand Bellevue 

  • 3 breakfasts 

  • 2 lunches on Wednesday and Thursday 

  • Networking dinner on Wednesday evening 

  • Gala Dinner on Thursday evening 

  • Coffee breaks during the conference at Le Grand Bellevue

  • Transfer service during the conference days from Le Grand Bellevue to locations in Gstaad

  • Access to the LIC networking and matchmaking app

 

The ticket does NOT includes:

  • Travel service to and from Gstaad

DELUXE ROOM*

DELUXE ROOM

Package with accommodation

Regular Price:         4100 CHF

Early bird:               3500 CHF

Includes:

  • 2-nights stay in a Deluxe room at Le Grand Bellevue

  • 3 breakfasts 

  • 2 lunches on Wednesday and Thursday 

  • Networking dinner on Wednesday evening

  • Gala Dinner on Thursday evening 

  • Coffee breaks during the conference at Le Grand Bellevue

  • Transfer service during the conference days from Le Grand Bellevue to locations in Gstaad

  • Access to the LIC networking and matchmaking app

 

The ticket does NOT includes:

  • Travel service to and from Gstaad

CONFERENCE-ONLY

CONFERENCE ONLY

Package without accommodation

Regular Price:         3500 CHF

Early bird:               2900 CHF

Includes:

​​​

  • 3 breakfasts 

  • 2 lunches on Wednesday and Thursday 

  • Networking "flying-dinner" on Wednesday evening 

  • Gala Dinner on Thursday evening 

  • Coffee breaks during the conference at Le Grand Bellevue

  • Transfer service during the conference days from Le Grand Bellevue to locations in Gstaad

  • Access to the LIC networking and matchmaking app

The ticket does NOT includes:

  • Travel service to and from Gstaad

  • Accommodation

*If you would like to get a room upgrade to a Suite, please contact us at info@longevityinvestors.ch and we will send you further information.

**We have preferential rates with Le Grand Bellevue should you wish to extend your stay.

We are happy to support you with accommodation and travel service arrangements.

Please contact info@longevityinvestors.ch for more information.

 

Recent Speakers 

We had the honor to welcome the leading longevity industry experts and scientists at the conference

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Ph.D., A.O. David A. Sinclair

David Sinclair is a tenured Professor of Genetics at Harvard Medical School. He is best known for his work on genes and small molecules that delay aging by boosting the body’s defenses and for being the first reprogram and rejuvenate tissuesin vivo.

He has published over 200 scientific papers, is a co-inventor on over 50 patent and patent applications, and has co-founded a dozen biotechnology companies in the areas of rare diseases, inflammation, vaccines, infectious disease detection, eye diseases, diabetes, fertility, cancer, and biosecurity.

His first book Lifespanbecame a New York Times best seller in 2019. He has a citation index (h-index) of 94, serves as founder and Co-Chief Editor of the scientific journal Aging, is a board member of companies, and has received 36 awards including being one of Australia's leading scientists under 45, the Australian Medical Research Medal, the NIH Director’s Pioneer award, TIME magazine’s list of the “100 most influential people in the world” and the “Top 50 people in healthcare.” In 2018, he became the equivalent of a knight as an Officer of the Order of Australia (AO) for his work in medical research, science communication, and national security. 

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Sergey Young

Sergey Young is a longevity investor and visionary with a mission to extend healthy lifespans of one billion people. To do that, Sergey founded Longevity Vision Fund to accelerate life extension technological breakthroughs and to make longevity affordable and accessible to all Sergey is on the Board of Directors of the American Federation of Aging Research (AFAR) and the Development Sponsor of AGE REVERSAL XPRIZE global competition designed to cure aging. Sergey is also a Top-100 Longevity Leader, who is transforming the world, one workplace at a time, with Longevity@Work – the first non-profit corporate longevity program of its kind.
Sergey Young has been featured as a top longevity expert and contributor on CNN, Fox News, and Forbes. As the author of books such as ‘The Science and Technology of Growing Young’ and the mastermind behind the online life extension platform SergeyYoung.com, Sergey is passionate about sharing news from the exciting world of longevity

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Aubrey de Grey

Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process.

He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging.



He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage.

Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits (uncompensated) on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Jim Mellon

Jim Mellon is a British entrepreneur and investor with a wide range of interests. Through his private investment company, Burnbrae Group, he has substantial real estate holdings in Germany and the Isle of Man, as well as holdings in private and public companies.

Jim’s investment philosophy is underpinned by his ability to recognise emerging trends that give rise to new industries or major shifts in markets. This includes global financial crisis of 2008-2009, as foreseen in the first book Jim co-authored entitled Wake Up!, and subsequently in the new science and technologies detailed in Cracking the Code and Fast Forward. 

More recently Jim has established himself as a leader in the nascent field of ageing research and longevity.  His groundwork into the field is summarised in the book Juvenescence which he also co-authored.

Jim sits on the Board of Trustees of the Buck Institute for Research on Aging, and the American Federation for Aging Research (AFAR).  He is also a trustee of Biogerontology Research Foundation and Lifeboat Foundation, is an Honorary Fellow of Oriel College at the University of Oxford and sits on the Advisory Board of the Milken Institute’s Centre for the Future of Aging. Jim has been honoured by the AFAR with the George E. and Marie J. Doty Award for his support of ageing research.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Brian Kennedy

Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of detecting, delaying, preventing and treating human aging and associated diseases. He is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore and serves as Director of (1) the Centre for Healthy Longevity at the National University Health System, (2) the Healthy Longevity Translational Research Program, and (3) the NUS Bia-Echo Asia Centre for Reproductive Longevity and Equality. Collectively, NUS aging research seeks to demonstrate that longevity interventions can be successfully employed in humans to extend healthspan, the disease-free and highly functional period of life. From 2010 to 2016, Dr. Kennedy was the President and CEO of the Buck Institute for Research on Aging and he maintained a professorship there through 2020. Dr. Kennedy has an adjunct appointments at the Department of Biochemistry at the University of Washington, where he was a faculty member from 2001 to 2010. In addition, Dr. Kennedy is also actively involved with a number of Biotechnology companies. In addition, Dr. Kennedy serves as a Co-Editor-In-Chief at Aging Cell.

Finally, Dr. Kennedy has a track record of interaction in China, where he was a Visiting Professor at the Aging Research Institute at Guangdong Medical College from 2009 to 2014. His Ph.D. was performed in the laboratory of Leonard Guarente at M.I.T., where he published the first paper linking Sirtuins to aging.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Eric Verdin

Dr. Eric Verdin is the President and Chief Executive Officer of the Buck Institute for Research on Aging. A native of Belgium, Dr. Verdin received his Doctorate of Medicine from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Gladstone Institute at the University of California San Francisco (UCSF). Dr. Verdin is currently adjunct Professor of Medicine at UCSF and Adjunct Professor at the University of Southern California (USC).



Dr. Verdin studies how metabolism, diet, and small molecules impact epigenetic regulatory mechanisms, and thereby the aging process and its associated diseases. He is a highly cited scientist (top 1 percent) and has been recognized for his research with multiple awards including a fellowship from the American Association for the Advancement of Science, election to the American Society for Clinical Investigation, the Association of American Physicians, and Belgium’s Royal Academy of Medicine. 

The Buck Institute, in the San Francisco Bay Area, is globally recognized as the pioneer and leader in the field of research on aging, the number one risk factor for chronic disease. For more information visit www.buckinstitute.org

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Dina Radenkovic

Dina is an academic medical doctor by background, working as an investor and entrepreneur in the field of aging. She is a General Partner at the Programmable Biology SALT Fund. She is a co-founder & Chief Science Officer Hooke, an elite longevity research clinic in London launched in partnership with Dr Eric Verdin from the Buck Institute for Research on Aging. She is also a senior scientist at the Buck Artificial Intelligence applied to the Biology of Aging Platform where they study novel biomarkers of biological aging.

Dina qualified with a dual degree in medicine and physiology from UCL Medical School, with the elective at the New England Journal of Medicine, Harvard University, awarded number one in preclinical medicine and the best overall performance in physiology BSc. She has led two projects, digital therapeutics company for women and an algorithm for cardiac MRI to major industry acquisitions. She later worked as Research Fellow at King's College London and at Harvard University. Dina did her residency at St Thomas’ Hospital in London. She has over 30 academic papers, 7 grants and over 40 scientific conference presentations. She is fluent in 5 languages and 3 programming languages.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Nir Barzilai

Dr. Nir Barzilai serves as director of the Institute for Aging Research at the Albert Einstein College of Medicine. In addition, he is a founder and board member of CohBar Inc. Listed on the Russel 2000 Index, it develops therapeutics based on mitochondrial-derived peptides. He is a renowned expert and scientist in the study of the biology and genetics of aging.

He is also a founder and a Medical Consultant to Lifebiosciences, targeting therapeutics against the hallmark of aging. He is leading the TAME (Targeting Aging with MEtformin) multi-central study to show that aging can be a target in humans in support of changing the FDA indication that is relevant to targeting aging.

Dr. Barzilai is the recipient of many awards including the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity Award. His work has been profiled by outlets such as the New York Times, BBC, PBS, and National Geographic. He received his MD from Technion-Israel Institute of Technology.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Prof. João Pedro de Magalhães

Prof de Magalhaes graduated in Microbiology in 1999 from the Escola Superior de Biotecnologia in his hometown of Porto, Portugal, and then obtained his PhD in 2004 from the University of Namur in Belgium. Following a postdoc with genomics pioneer Prof George Church at Harvard Medical School, in 2008 Prof de Magalhaes was recruited to the University of Liverpool. He now leads the Integrative Genomics of Ageing Group (http://pcwww.liv.ac.uk/~aging/). His lab studies the ageing process and how we can manipulate it to fend off age-related diseases and improve human health.

Prof de Magalhaes has authored over 100 publications and given over 100 invited talks, including three TEDx talks. He also makes regular media appearances (BBC, CNN, the Washington Post, the Financial Times and many others). Prof de Magalhaes is an advisor/consultant for various organizations, including nonprofit foundations, universities, investment funds and biotech companies.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Raiany Romanni

Raiany Romanni is a researcher in bioethics at Harvard Medical School (HMS), where she focuses on the ethical implications of longevity research conducted in HMS labs and beyond.

Raiany has published extensively on the subject of death, with articles in philosophical journals dealing with theories from Freud to Nietzsche, and most recently, the ABC article on the ethics behind life-extending technologies, which received nearly 100,000 views in one week. For her PhD dissertation in German Philosophy, at Brown University, she is working on a non-fiction book that investigates why 21st century, secular humans insist on narrating aging as a mystical, tabooed phenomenon.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

James Peyer

James Peyer is the Chief Executive Officer and Co-Founder of Cambrian Biopharma. He also serves as the Chairman of the Board of Sensei Biotherapeutics and board and executive roles across Cambrian’s pipeline. He has spent his entire life dedicated to the mission of finding ways of preventing people from getting diseases like cancer and Alzheimer’s instead of waiting for people to get sick. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. Prior to Apollo, James was a biotech R&D specialist at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his B.A. with special honors from the University of Chicago.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Prof. Andrew J. Scott

Andrew J. Scott is Professor of Economics, former Deputy Dean at London Business School and Research Fellow at the Centre for Economic Policy Research.

His research focuses on longevity, an ageing society, and fiscal policy and debt management and has been published widely in leading journals. His book with Lynda Gratton, The 100-Year Life, has been published in 15 languages, is an Amazon bestseller and was runner up in the FT/McKinsey Business Book of the Year Award 2016 and Japanese Business Book of the Year Award 2017. His recent 2020 book, The New Long Life, considers how the challenges and opportunities of social and technological ingenuity might shape a new age of longer lives.

He is currently on the advisory board of the UK’s Office for Budget Responsibility, the Cabinet Office Honours Committee (Science and Technology), co-founder of The Longevity Forum, a member of the UK government’s Longevity Council and the WEF council on Japan and a consulting scholar at Stanford University’s Center on Longevity.

His ground-breaking work on longevity, economics, and the value and effect technology and longevity combined, will have on the wider society, is shaped by his professional connections to academia, industry, social pioneers and policymakers around the world.

Andrew previously held positions at Oxford University, London School of Economics and Harvard University. His MA is from Oxford, his M.Sc. from the London School of Economics and his D.Phil from Oxford University.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Prof. Dr. Collin Y. Ewald

Collin has a longstanding interest in the molecular biology of healthy aging and age-related pathologies. He has more than 15 years of experience in drug discovery and high-throughput screening promoting lifespan extension. He is the founder and currently the president of the Swiss Society for Aging Research (www.ssfar.ch). He has received multiple awards, including NYAS Future Entrepreneur recognized by the New York Academy of Sciences, and is named under the top 1000 Longevity Leaders world-wide and the top 15 Longevity Influencers in Switzerland.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Wei-Wu He

Dr. Wei-Wu He has been serving as Executive Chairman of Human Longevity Inc. since July 2019. Dr. He is currently the Chairman of CASI Pharmaceuticals, Inc., OriGene, Juventa, Sophonix and founder of Genetron Health; Dr. He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established since 2000.
In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 50 research publications and inventor of over 32 issued patents.
Dr. Wei-Wu He received his PhD in Molecular Biology from Baylor College of Medicine and received an MBA degree from the Wharton School.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Andrea B. Maier

Andrea Maier, a Fellow of the Royal Australasian College of Physicians (FRACP), graduated in Medicine (MD) 2003 from the University of Lübeck (Germany), was registered 2009 in The Netherlands as Specialist in Internal Medicine-Geriatrics and was appointed Full Professor of Gerontology at Vrije Universiteit Amsterdam (The Netherlands) in 2013. She was the head of Geriatrics at the Vrije Universiteit Medical Center from 2012 to 2016. From 2016 to early 2021 Professor Maier served as Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital, Australia, and as Professor of Medicine and Aged Care at the University of Melbourne, Australia. She continued her career at the National University of Singapore as Co-Director of the Centre for Healthy Longevity. Professor Maier’s research focuses on unraveling the mechanisms of ageing and age-related diseases. During the last 10 years she has conducted multiple international observational studies and intervention trials and has published more than 300 peer-reviewed articles, achieving an H index of 54, spearheading the significant contributions of her highly acclaimed innovative, global, multidisciplinary @Age research group. She is a frequent guest on radio and television programs to disseminate aging research and an invited member of several international academic and health policy committees. She currently is the President of The Australian and New Zealand Society for Sarcopenia and Frailty Research.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Alexandra Bause

Alexandra is a Co-Founder and Investment Director at Apollo Health Ventures, an early stage investment fund focused on developing interventions that enhance human health and longevity.

As a trained pharmacist and biomedical science PhD, Alexandra has always been following her passion for improving healthy longevity. Her PhD studies at Harvard Medical School were focused on investigating the molecular mechanisms that contribute to cellular aging and could be targeted to increase mammalian health span. After her PhD, Alexandra worked with The Boston Consulting Group where she specialized on Pharma and Biotech Strategy to drive the development of innovative therapeutics.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Joon Yun

Dr. Joon Yun is President and Managing Partner of Palo Alto Investors, LP, a hedge fund founded in 1989 with approximately $2 billion in assets invested in healthcare.

Board certified in radiology, Joon served on the clinical faculty at Stanford from 2000-2006. Joon has served on numerous boards, and he is currently a trustee of the Salk Institute. Joon and his wife Kimberly launched the $1 million Palo Alto Longevity Prize and donated $2 million to support the National Academy of Medicine's Longevity Grand Challenge. He received his M.D. from Duke Medical School and B.A. from Harvard College.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Michael A. Smith

Dr. Michael A. Smith received his medical doctorate from the University of Texas, Southwestern Medical Center. Dr. Smith practiced Internal Medicine and Radiology in Dallas, Texas in the early 2000s and then transitioned to the pharmaceutical and nutraceutical industries as an educator and consultant. Dr. Smith currently is the Director of Education and Spokesperson for Life Extension® and is the author of The Supplement Pyramid: How to Build your Personalized Nutritional Regimen.. He is also the host of Live FOREVERish, a podcast and Facebook live show for Life Extension®.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Maria Konovalenko

Maria Konovalenko is a Scientist in Residence at Formic Ventures, a diversified venture capital firm that makes early stage investments in biotechnology startups focused on human longevity as well as technology startups and companies that make human lives more meaningful. Maria’s obtained her PhD in biology of aging in a joint program between University of Southern California and the Buck Institute for Research on Aging. Her research was focused on aging of stem cells in respiratory epithelium as well as the overlap between mTOR signaling and cellular senescence.

Maria has been involved in fighting aging since 2008. She is one of the organizers of the Genetics of Aging and Longevity Conference series. Maria was part of team at the science for Life Extension Foundation, a Moscow-based non-profit, since 2008 to 2016 and has been raising funding for longevity and regenerative medicine research from both government and private sources.

Maria's background is in molecular biophysics, she got both her Bachelor's and Master's degrees from Moscow Institute of Physics and Technology. Maria's goal is to make people live as long and as healthy as possible using the advances of science and technology.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Ronjon Nag

Ronjon Nag is founder of R42 Institute and is an Interdisciplinary Distinguished Careers Institute Fellow at Stanford University where he teaches courses for AI in healthcare. He has invented and deployed artificial intelligence systems for over three decades.

He received a PhD in engineering from Cambridge, an MS from MIT, the IET Mountbatten Medal at the Royal Institution, and was a Harkness Fellow at Stanford University. Companies he has co-founded or advised have been sold to Motorola, BlackBerry, and Apple.  

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Dr. Morten Scheibye-Knudsen

For Dr Scheibye-Knudsen, associate professor, University of Copenhagen, aging is the largest risk factor for most diseases and damage to our genome is likely the cause of aging. He is focused on exploring the physiological consequences of DNA damage and what we can do to intervene in genotoxic insults. His goal is to understand, modulate, and treat aging and age-related diseases.
Morten earned his MD in 2007 from the University of Copenhagen where he also earned his DMSc (Doctor of Medical Sciences, higher doctorate) in Neurodegeneration in Accelerated Aging in 2016.
In 2008, Morten became Postdoctoral Fellow in the laboratory of Vilhelm Bohr at the National Institute on Aging, NIH, in Baltimore, Maryland. His work focused on the cross-talk between DNA repair and mitochondrial function in neurodegeneration and aging. In 2013, at NIH, he became Research Fellow and in 2015, Visiting Professor.
For six years, Morten lectured on the Biological Basis of Aging for graduate students at Johns Hopkins Bloomberg School of Public Health.
In addition to his academic activities Morten manages his companies Forsoegsperson.dk and Mitodb.com, is a board member at the Longevity Vision Fund and Molecule Protocols, and serves as Chief Editor at Frontiers Media.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Prof. Evelyne Yehudit Bischof, MD, MPH, FEFIM, FMH

Prof. Evelyne Bischof is a chief physician associate of internal medicine at University Hospital Renji of Jiaotong University Shanghai and concierge longevity physician for executive longevity patients.Currently she is also affiliated with the International Center for Multimorbidity and Complexity in Medicine (ICMC), Universität Zürich, and was prev. senior physician of internal medicine at the University Hospital Basel. She is a Swiss board certified (FMH) trained in Europe, USA and China (Harvard Medical School affiliated hospitals (Mass General Hospital, Beth Israel MD, Dana Farber Institute) and Columbia University NYC; Tongji University hospitals, Shanghai and University Hospitals of Zurich and Basel (Switzerland).Her research focus is oncology and longevity medicine, Artificial Intelligence (AI) and digital health, precision medicine, biogerontology, and geronto-oncology. She published over80 peer-reviewed papers, is frequent speaker at scientific and medical conferences in Asia and Europe. Long term member of various medical societies, e.g. European Federation of Internal Medicine, World Academy of Medical Sciences, Swiss Society of Internal Medicine etc. Evelyne spent a decade practicing medicine, lecturing at medical schools and performing clinical and translational research in New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice at the following well-known and highly reputable institutions: University Hospital of Basel, Fudan Cancer Institute and Hospital; Zhongshan Hospital, Renji Hospital and Shanghai East Hospital. She sits on several scientificand advisory boards of biotech and longevity hubs.

GREG%20HUNG_edited.png
Bildschirmfoto 2021-05-05 um 18.02.35.pn
Bildschirmfoto 2021-05-05 um 18.02.16.pn

Phil Newman

As Editor-in-Chief of www.Longevity.Technology Phil oversees daily news and market research to address the crossover between longevity science and investment. This news platform has fast become the #1 for daily news and insights.

As founder of First Longevity (which owns www.Longevity.Technology) Phil and his team help to prepare longevity science and technology businesses for equity funding ahead of introducing deals to, and syndicating deals among, VCs, family offices, and HNWs.

Prior to focusing exclusively on longevity, Phil has applied his marketing and business development expertise at c-level into: IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability markets.

 
 

Agenda 2022

Coming soon

f9672f00-2c21-4c00-a26f-a2d25fa6abaf_edited.jpg

Location: Gstaad

Come up, slow down – the slogan describes what Gstaad is all about.

With its top hotels, gourmet restaurants, luxury chalets and nearby Saanen airport, this traffic-free holiday village is popular with HNWI from all over the world.

Gstaad is hard to beat; it’s a place where guests and locals are in harmony with nature and can enjoy the charms of the surroundings.

 

Venue: Le Grand Bellevue 

LIC is partnering up with one the top luxury hotels in Gstaad: Le Grand Bellevue.

The LIC delegates can enjoy a 2-night stay in a luxurious room or a suite, access to over 3,000 square metres of rejuvenating SPA facilities, and dining experiences in hotel’s gourmet restaurants.

hotel_edited.jpg
 
  • Twitter
  • LinkedIn

Press

 

Team

Tobias.jpg

Dr. Tobias Reichmuth

Founding Partner

  • Twitter
  • LinkedIn
Marc.jpg

Marc P. Bernegger

Founding Partner

  • Twitter
  • LinkedIn
Photo Marco and Alex (1)_edited_edited.jpg

Alexandra Ezhkova

Head of Events

  • LinkedIn
EMAIL.png
 

Contact

For more information please contact us.

Thank you for your request!

Stay in the loop

Thanks for submitting!

Powered by

maximon Final.png

© 2020 by Longevity Investors Ltd. in Zug, Switzerland info@longevityinvestors.ch